Aphria (NYSE:APHA) was downgraded by equities researchers at Eight Capital to a “hold” rating in a research note issued on Thursday. They currently have a $7.00 price target on the stock. Eight Capital’s price target would suggest a potential upside of 27.04% from the company’s previous close.
Separately, Canaccord Genuity reaffirmed a “buy” rating on shares of Aphria in a report on Wednesday, December 5th.
Shares of APHA stock traded down $0.30 on Thursday, hitting $5.51. 77,548 shares of the company’s stock traded hands, compared to its average volume of 8,569,202. Aphria has a one year low of $3.75 and a one year high of $19.87.
Aphria Company Profile
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Featured Article: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.